Skip to main content
Fanli Digital Technology Co., Ltd logo

Fanli Digital Technology Co., Ltd — Investor Relations & Filings

Ticker · 600228 ISIN · CNE000000Y78 Shanghai Stock Exchange Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 2,251 across all filing types
Latest filing 2020-07-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600228

About Fanli Digital Technology Co., Ltd

https://corp.fanli.com/

Fanli Digital Technology Co., Ltd. provides e-commerce integration and digital marketing services. The company operates a comprehensive platform that connects consumers with various online retail ecosystems through value-added services such as cash-back rewards, discount coupons, and promotional insights. Its core business model focuses on performance-based marketing, utilizing data-driven strategies to facilitate sales conversions for brand partners. Key offerings include brand promotion, user loyalty management, and targeted advertising solutions. By integrating diverse shopping channels into a single interface, the company optimizes the consumer purchasing journey and provides brands with scalable traffic acquisition tools. The platform serves as a strategic intermediary, leveraging user behavioral data to enhance marketing efficiency and provide measurable returns for merchants while delivering cost savings to a broad user base.

Recent filings

Filing Released Lang Actions
杭州同美股权投资基金合伙企业（有限合伙）《关于江西昌九生物化工股份有限公司股票交易异常波动询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations of Jiangxi Changjiu Bio-chemical Co., Ltd. It states that no undisclosed major information or transactions exist and denies any trading activity during the abnormal period. The content is a formal reply to a regulatory inquiry rather than a financial report or announcement of a report. It does not contain financial data, management changes, voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a compliance-related response to a regulatory inquiry about stock trading activity.
2020-07-14 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a listed company (Jiangxi Changjiu Biochemical Co., Ltd.) regarding abnormal stock price fluctuations over several trading days. It details the company's investigation into the causes, confirms no undisclosed material information beyond a major asset restructuring plan, and discusses related risks. The document references regulatory inquiries and ongoing approval processes for a major asset restructuring and related financing. It is not a full financial report, earnings release, or management discussion but rather a regulatory disclosure about stock price abnormality and related corporate events. The document length is about 4,296 characters, which is relatively short and focused on a specific regulatory disclosure. This fits the profile of a Regulatory Filing (RNS) as it is a compliance announcement about stock trading irregularities and related corporate matters, not a full report or financial statement.
2020-07-14 Chinese
江西昌九集团有限公司《关于江西昌九生物化工股份有限公司股票交易异常波动的询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a formal response letter regarding an inquiry about abnormal stock trading fluctuations. It explicitly states that no undisclosed major information or transactions exist and denies any trading activity during the abnormal period. The content is a regulatory communication addressing stock trading concerns rather than a financial report, management change, or other specific filings. The document is short (424 characters) and serves as a regulatory response to a stock exchange inquiry, fitting best under Regulatory Filings (RNS).
2020-07-14 Chinese
关于参加2020年投资者集体接待日的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (653 characters) about the company's participation in a 2020 investor collective reception day event organized by the Jiangxi Listed Companies Association. It includes details about the event date, time, participants, and a web link for online interaction. There is no financial data, no detailed report, no voting results, no management changes, or other regulatory filings. The document serves as an announcement informing investors about the event rather than a report or transcript. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-07-10 Chinese
重大资产置换、发行股份及支付现金购买资产、募集配套资金暨关联交易预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易预案（修订稿）" which translates to "Major Asset Swap, Issuance of Shares and Payment of Cash to Purchase Assets and Raising Supporting Funds and Related Party Transaction Proposal (Revised Draft)". It is a detailed proposal document related to a major asset restructuring involving asset swaps, share issuance, cash payments, and fundraising. The document includes detailed sections such as transaction overview, parties involved, asset details, financial data, risk factors, and legal and regulatory compliance statements. It references regulatory bodies such as the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange, and discusses approvals and procedures required for the transaction. The document is not a simple announcement but a comprehensive plan and proposal for a major corporate restructuring transaction. This fits the category of a Capital/Financing Update (CAP) as it involves issuance of shares, asset purchases, and fundraising activities. It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement or voting result. Therefore, the appropriate classification is CAP with high confidence.
2020-07-08 Chinese
上会会计师事务所（特殊普通合伙）关于关于对上海证券交易所《关于对江西昌九生物化工股份有限公司重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易预案信息披露的问询函》中有关事项的说明
Audit Report / Information Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shanghai Stock Exchange regarding a major asset swap, share issuance, cash payment for asset purchase, and related-party transaction plan involving Jiangxi Changjiu Bio-chemical Co., Ltd. It includes extensive financial audit information, legal risk disclosures, contract details, litigation and arbitration cases, administrative penalties, and compliance with regulatory requirements. The content is focused on audit findings, legal and compliance issues, and risk assessment related to a specific transaction and the target company's business operations. There is no indication that this is a full annual or interim financial report, earnings release, or a presentation. The document is a standalone audit-related report addressing regulatory inquiries and providing audit opinions and risk disclosures. Therefore, it fits best under the category of Audit Report / Information (AR).
2020-07-08 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.